Its been struggling, for sure, but this might be the tailwind it needs to make it attractive again, especially with up to 6 million lapsed members that have expressed willingness to pay to lose weight and who could be brough back in by marketing campaigns like this below (combined with the general social media reflexivity noted above with GLP-1 drugs): Dating Sites & Apps Its perhaps uncomfortable to confront but with nearly a third of every single person in the U.S
Experts from UT Southwestern, University of Colorado, Cato Institute, and Obesity Action Coalition share what evidence currently shows about GLP-1 function and effectiveness and discuss how to ensure patient access, affordability, and safety
Studies with semaglutide show that discontinuation leads to appetite returning to baseline levels and weight regain of approximately two-thirds of the lost weight within one year
GLP-1 Cost Management, Coverage, and Demand Skyrocketing costs are one challenge
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): A double-blind, phase 3b, randomised controlled trial
Weight loss-only indications face significant barriers in public provincial plans
